Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy and Immunology
Enrollment initiated for phase 1 trial for inhaled asthma product
July 25th, 2005
Lab International Inc., a drug development company with subsidiaries focused on developing therapies for the inhalation market and on contract research services, announced that it has initiated enrollment in a phase 1 trial for its asthma product LAB CGRP (calcitonin gene related peptide). The placebo controlled dose escalation study is being conducted in a single center in Europe to investigate the safety and tolerability of inhaled CGRP. A total of 10 healthy volunteers will be enrolled in the study. This phase 1 trial is expected to be completed in time for the company to file an investigational new drug (IND) application or equivalent prior to initiating a phase 2...
Source: Health & Medicine Week (2005-07-25)
|
